After decades of limited research and legal roadblocks to medical and recreational use, psychedelic drugs are rapidly remerging as treatments of interest in psychiatry. We interviewed two experts in the field.
Sandhya Prashad, MD discusses how leveraging teletherapy has helped providers and patients troubleshoot common concerns around social distancing and has gotten many first-time patients in the “virtual” door.
The Food and Drug Administration (FDA) has approved Nourianz (istradefylline; Kyowa Kirin) tablets as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson disease (PD) experiencing “off” episodes.
Prices of prescription drugs in short supply between 2015 and 2016 were found to increase more than twice as quickly as they would have in the absence of a shortage.
The difference in spending by Medicare on brand-name combination medications and the cost of the equivalent generic constituents was an estimated $925 million for 2016.
The use of specialist services may allow more equitable solutions to treatment questions in critically ill children as they are less formal and adversarial than the courts.
While politicians celebrate the passage of the Right to Try Act, physicians must closely monitor the outcomes to mitigate the potential consequences of this law.
“Irrational” treatment decisions are sometimes made based on rewards, risk, and potential therapeutic trade-offs.
The radioactive drug is approved to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
The oral solution will replace a compounding kit used to prepare vancomycin oral liquid therapy.
